Life Therapeutics to move more operations to US
27 July, 2005 by Ruth BeranLife Therapeutics (ASX:LFE) will relocate two of its three business divisions from Sydney to Atlanta, Georgia in the USA by March 31, 2006.
Metabolic raises another $4.04 million
21 July, 2005 by Ruth BeranMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has raised AUD$4.04 million in its share purchase plan (SSP) which closed last Friday.
ChemGenex announces two new cancer trials
19 July, 2005 by Helen SchullerChemGenex Pharmaceuticals (ASX:CXS) has outlined its accelerated clinical development plan for its lead anti-cancer therapeutic Ceflatonin, following positive results from initial trials.
Meditech IDs new breast cancer target
19 July, 2005 by Graeme O'NeillVictorian cancer biopharma Meditech Research (ASX:MTR) claims to have identified a hot new target for breast cancer therapy -- an enzyme called hyaluronic synthase 2 (HAS2), found in vesicles in cell membranes.
Market will see a very different Amrad: chairman
15 July, 2005 by Ruth BeranSince CEO Pete Smith and chairman Bob Moses resigned in May, Amrad (ASX:AML) has kept quiet about its strategic direction. Ruth Beran spoke to chairman Ian Davis about the refocusing of the company.
Proteome Systems reports positive results for Alzheimer's compound
15 July, 2005 by Graeme O'NeillSydney proteomics R&D company Proteome Systems (ASX:PXL) has reported positive results from pre-clinical trials of its lead compound, the potent antioxidant EUK-189, in an animal model of Alzheimer's disease.
'What fatigue?' Auckland Health offers view of GTG settlement
12 July, 2005 by Graeme O'NeillThe Auckland District Health Board has offered its own perspective on the out-of-court settlement of its dispute with Victorian biotech Genetic Technologies (ASX:GTG) over GTG's request for AUD$12 million in licensing and royalty payments for NZ agencies using its proprietary gene-testing and gene-mapping technologies.
Neuren extends US partnership
11 July, 2005 by Graeme O'NeillPreclinical trials of Auckland biopharma Neuren's (ASX:NEU latest neuroprotectant, NNZ-2566, have convinced the US Army's Walter Reed Research Institute in Washington to back a clinical trial of the new drug in brain-trauma patients.
Hughes grants flow to local malaria researchers
11 July, 2005 by Graeme O'NeillThe latest list of international research grants from the Howard Hughes Medical Institute (HHMI) has confirmed Australia's status as a leading nation in malaria research.
Meditech signs collaboration agreement with US firm Hyalose
08 July, 2005 by Helen SchullerCancer therapy developer Meditech (ASX:MTR) has signed a research and development collaboration agreement with Hyalose, a privately-owned US biotech company.
WEHI to share in US$21 million Gates grant for malaria research
07 July, 2005 by Ruth BeranProf Alan Cowman and his team at The Walter and Eliza Hall Institute of Medical Research (WEHI) are part of an international consortium that has won a US$13 million Grand Challenge in Global Health grant to develop a treatment for malaria.
Life Therapeutics sets out to acquire US firm Pyramid Biological
04 July, 2005 by Ruth BeranSydney-based Life Therapeutics (ASX:LFE) has firmed up its stake in the global plasma supply industry, issuing a definitive letter of intent to acquire privately-held California-based Pyramid Biological for US$13 million, plus assumption of US$7 million debt.
In brief: Acrux, Psiron, Circadian
29 June, 2005 by Ruth BeranAcrux (ASX:ACR) has received a US$1 million milestone payment from Vivus for its estradiol transdermal spray product Evamist, currently in Phase III clinical trials to treat menopausal symptoms in the US, which was due today.
Gates Foundation funds UQ dengue research
28 June, 2005 by Graeme O'NeillUniversity of Queensland parasitologist Prof Scott O'Neill has won a prestigious grant from the Bill and Melinda Gates Foundation in the US to work on a remarkable symbiotic bacteria that induces sterility in insects.
Brain pacemaker could ease severe depression - study
28 June, 2005 by Staff WritersPatients suffering from severe depression who have not responded to other treatments may be helped by deep brain stimulation, researchers said.
